Nuvectis Expands Portfolio via License Agreement with Haisco Pharmaceutical Group for Two Clinical-Stage Compounds
Nuvectis has entered a licensing agreement with Haisco Pharmaceutical Group to acquire ex-China rights for two clinical-stage compounds, NXP100 (a Complement Factor B inhibitor) and NXP200 (a paradox breaker BRAF inhibitor). This deal positions Nuvectis as a late-stage development company in complement-mediated diseases and oncology. Both compounds show strong potential with ongoing trials across multiple indications.
Topics: clinical-stage compounds license agreement pipeline expansion